TherAchon AG

Therachon is a global biotechnology company (headquartered in Basel) committed to making a difference in the lives of patients living with serious rare conditions. Therachon is assembling a growing best-in-disease pipeline that shows great promise in both Achondroplasia (short-limbed dwarfism, which affects 250'000 worldwide) and Short Bowel Syndrome. TA-46 for the therapy of achondroplasia developed by Therachon has completed clinical phase 1 and received Orphan Drug Designation from the European Medicines Agency and the U.S. Food and Drug Administration. As a result of Therachon's outstanding work, Therachon was acquired by Pfizer in 2019 for USD 340 million (milestones not inclued). Bevor being acquired by Pfizer, Therachon spun-off its apraglutide development program into a separate, independent company called VectivBio also headquartered in Basel. This program for short bowel syndrome is currently in Phase 2 development.